Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 755.75

+2.5%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	3/3/2017 2:48:17 AM
	Read Replies (1) of 3559

Sanofi Antibody Collaboration: They did not want REGN222, but they did pay extra for MEDI8897???!!!! Sanofi Pasteur and MedImmune Collaborate on Monoclonal Antibody to Prevent Illnesses Associated with RSV - Respiratory Syncytial Virus is the most common cause of lung inflammation and pneumonia in infants - *http://finance.yahoo.com/news/sanofi-pasteur-medimmune-collaborate-monoclonal-070101369.html* *Many months ago, I said..."BEGINNING OF THE END"! Let that come as soon as possible.* REGN had 2 FDA inspection at 2016 year -end: https://fdazilla.com/inspections/database/1000521995-20161130 *https://fdazilla.com/inspections/database/1000514603-20161104* Probably due to Suri/Dupi BLA. NO 483 issue. Cut Sanofi out and let French decay alone! PS: I must confess, I am D.SICK of FUCXX FRENCH!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next